SI1730146T1 - Azaindoli, uporabni kot zaviralci jak-a in drugih protein-kinaz - Google Patents
Azaindoli, uporabni kot zaviralci jak-a in drugih protein-kinazInfo
- Publication number
- SI1730146T1 SI1730146T1 SI200531340T SI200531340T SI1730146T1 SI 1730146 T1 SI1730146 T1 SI 1730146T1 SI 200531340 T SI200531340 T SI 200531340T SI 200531340 T SI200531340 T SI 200531340T SI 1730146 T1 SI1730146 T1 SI 1730146T1
- Authority
- SI
- Slovenia
- Prior art keywords
- jak
- inhibitors
- protein kinases
- azaindoles useful
- azaindoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55750304P | 2004-03-30 | 2004-03-30 | |
US62559904P | 2004-11-05 | 2004-11-05 | |
PCT/US2005/010846 WO2005095400A1 (en) | 2004-03-30 | 2005-03-30 | Azaindoles useful as inhibitors of jak and other protein kinases |
EP05756052A EP1730146B1 (en) | 2004-03-30 | 2005-03-30 | Azaindoles useful as inhibitors of jak and other protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1730146T1 true SI1730146T1 (sl) | 2011-09-30 |
Family
ID=34971569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200531340T SI1730146T1 (sl) | 2004-03-30 | 2005-03-30 | Azaindoli, uporabni kot zaviralci jak-a in drugih protein-kinaz |
Country Status (27)
Country | Link |
---|---|
US (6) | US7507826B2 (sl) |
EP (4) | EP2311837B1 (sl) |
JP (5) | JP4937112B2 (sl) |
KR (3) | KR101298967B1 (sl) |
CN (3) | CN101676285A (sl) |
AR (2) | AR048454A1 (sl) |
AT (1) | ATE508129T1 (sl) |
AU (3) | AU2005228904C1 (sl) |
BR (1) | BRPI0509369B1 (sl) |
CA (1) | CA2560454C (sl) |
CY (2) | CY1111716T1 (sl) |
DE (1) | DE602005027825D1 (sl) |
DK (2) | DK2332940T3 (sl) |
ES (2) | ES2398712T3 (sl) |
HK (2) | HK1098471A1 (sl) |
HR (1) | HRP20110566T8 (sl) |
IL (2) | IL177807A (sl) |
MX (1) | MXPA06011327A (sl) |
NO (2) | NO340403B1 (sl) |
NZ (2) | NZ549880A (sl) |
PL (2) | PL2332940T3 (sl) |
PT (2) | PT1730146E (sl) |
RS (1) | RS51830B (sl) |
RU (2) | RU2403252C2 (sl) |
SI (1) | SI1730146T1 (sl) |
TW (3) | TWI372624B (sl) |
WO (1) | WO2005095400A1 (sl) |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
PL2332940T3 (pl) | 2004-03-30 | 2013-03-29 | Vertex Pharma | Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
JP2008508303A (ja) | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | ピロロ−ピリジンキナーゼモジュレーター |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
CA2573573A1 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
US7855205B2 (en) * | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
WO2006063167A1 (en) | 2004-12-08 | 2006-06-15 | Smithkline Beecham Corporation | 1h-pyrrolo[2,3-b]pyridines |
US20060142572A1 (en) * | 2004-12-14 | 2006-06-29 | Gabriel Martinez-Botella | Inhibitors of ERK protein kinase and uses thereof |
WO2006087530A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
WO2006124863A2 (en) * | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
KR20080027775A (ko) | 2005-05-17 | 2008-03-28 | 플렉시콘, 인코퍼레이티드 | 피롤(2,3-b)피리딘 유도체 단백질 키나제 억제제 |
MX2007014619A (es) * | 2005-05-20 | 2009-02-13 | Vertex Pharma | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. |
CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
EP1926735A1 (en) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
KR20080083680A (ko) * | 2005-12-23 | 2008-09-18 | 스미스클라인 비참 코포레이션 | 오로라 키나제의 아자인돌 억제제 |
BRPI0706537A2 (pt) | 2006-01-17 | 2011-03-29 | Vertex Pharma | azaindóis úteis como inibidores de janus cinases |
EP1979353A2 (en) * | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
DE102006012617A1 (de) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
MX2008012860A (es) * | 2006-04-05 | 2009-01-07 | Vertex Pharma | Desazapurinas de utilidad como inhibidores de janus cinasas. |
CA2858520A1 (en) * | 2006-05-18 | 2007-11-29 | Pharmacyclics Inc. | Intracellular kinase inhibitors |
CN101573335A (zh) * | 2006-10-09 | 2009-11-04 | 武田药品工业株式会社 | 激酶抑制剂 |
EP2145878A3 (en) * | 2006-10-09 | 2010-02-24 | Takeda Pharmaceutical Company Limited | Aurora Kinase inhibitors |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
AU2007338574A1 (en) * | 2006-11-01 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | Tricyclic heteroaryl compounds useful as inhibitors of Janus kinase |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
EP2815750A1 (en) | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
WO2008080001A2 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
CA2681516A1 (en) | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of janus kinases |
BRPI0809500A2 (pt) | 2007-04-10 | 2014-09-23 | Sgx Pharmaceuticals Inc | Composto, e, métodos para modular a atividade de uma proteína quinase e para tratar uma doença |
JP2010528991A (ja) * | 2007-05-21 | 2010-08-26 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 複素環式キナーゼ調節因子 |
EP3495369B1 (en) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
DE102007028515A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009054941A1 (en) | 2007-10-25 | 2009-04-30 | Merck & Co., Inc. | Therapeutic compounds |
TWI446904B (zh) * | 2007-11-01 | 2014-08-01 | Acucela Inc | 用於治療眼科疾病及病症之胺衍生化合物 |
AU2008343173A1 (en) * | 2007-12-19 | 2009-07-09 | Aj Park | Pyrazolo [1,5-a] pyrimidines useful as JAK2 inhibitors |
WO2009145814A2 (en) * | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
SI2288610T1 (sl) | 2008-03-11 | 2016-11-30 | Incyte Holdings Corporation | Derivati azetidina in ciklobutana kot inhibitorji jak |
NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
AU2009274011B2 (en) * | 2008-07-23 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
WO2010011772A2 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
BRPI0916576A2 (pt) * | 2008-08-04 | 2017-06-27 | Chdi Inc | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. |
US20110166161A1 (en) * | 2008-09-18 | 2011-07-07 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
AU2009324894B2 (en) * | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
AR074870A1 (es) * | 2008-12-24 | 2011-02-16 | Palau Pharma Sa | Derivados de pirazolo (1,5-a ) piridina |
CR20170089A (es) | 2009-04-03 | 2017-07-17 | Plexxikon Inc | Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas |
US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
AU2016204286B2 (en) * | 2009-06-17 | 2018-02-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
RS57869B1 (sr) * | 2009-06-17 | 2018-12-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
CN102471345A (zh) * | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡嗪抑制剂 |
US8435980B2 (en) | 2009-07-15 | 2013-05-07 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
PT2486041E (pt) | 2009-10-09 | 2013-11-14 | Incyte Corp | Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo |
NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2011060216A1 (en) | 2009-11-12 | 2011-05-19 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
DE102009060174A1 (de) | 2009-12-23 | 2011-06-30 | Merck Patent GmbH, 64293 | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
EP2528916A1 (en) * | 2010-01-27 | 2012-12-05 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
WO2011094288A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
CN102869664A (zh) | 2010-01-27 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 吡唑并嘧啶类激酶抑制剂 |
MX2012008644A (es) * | 2010-01-27 | 2012-11-23 | Vertex Pharma | Inhibidores de cinasa de pirazolopiridinas. |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
WO2011109932A1 (en) * | 2010-03-09 | 2011-09-15 | F.Hoffmann-La Roche Ag | Novel process for the manufacture of 5-halogenated-7-azaindoles |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
US8779150B2 (en) | 2010-07-21 | 2014-07-15 | Hoffmann-La Roche Inc. | Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide |
EP2635557A2 (en) | 2010-11-01 | 2013-09-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
CA2822059A1 (en) * | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
RU2013132683A (ru) * | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
KR20140014110A (ko) | 2010-12-16 | 2014-02-05 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
CA2839937C (en) * | 2011-07-05 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
UA118010C2 (uk) * | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
MX364378B (es) | 2011-08-30 | 2019-01-21 | Chdi Foundation Inc | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso. |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2854879A1 (en) | 2011-11-07 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
DE102011119127A1 (de) * | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
IN2014CN04065A (sl) | 2011-11-23 | 2015-09-04 | Portola Pharm Inc | |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドAdvinus Therapeutics Limited | 置換された縮合三環式化合物、組成物およびその医薬用途 |
DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
WO2014074471A1 (en) | 2012-11-06 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
CN104918919A (zh) | 2012-11-21 | 2015-09-16 | Ptc医疗公司 | 取代的反向嘧啶Bmi-1抑制剂 |
WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
FR2999575A1 (fr) * | 2012-12-18 | 2014-06-20 | Centre Nat Rech Scient | 3,5-diaryl-azaindoles comme inhibiteurs de la proteine dyrk1a pour le traitement des deficiences cognitives liees au syndrome de down et a la maladie d'alzheimer |
WO2014110259A1 (en) | 2013-01-09 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Solid forms of a jak inhibitor |
FR3001219A1 (fr) * | 2013-01-22 | 2014-07-25 | Centre Nat Rech Scient | Inhibiteurs de kinases |
EA030705B1 (ru) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Способы и промежуточные соединения при получении ингибитора jak |
CA2901542C (en) * | 2013-04-02 | 2018-02-13 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
US9206188B2 (en) * | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
WO2014201332A1 (en) | 2013-06-14 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical combinations useful for treating rheumatoid arthritis |
WO2015018507A2 (en) * | 2013-08-07 | 2015-02-12 | Pharmathen S.A. | A novel process for the preparation of febuxostat |
ES2792549T3 (es) | 2013-08-07 | 2020-11-11 | Incyte Corp | Formas de dosificación de liberación sostenida para un inhibidor de JAK1 |
KR20160045070A (ko) | 2013-08-22 | 2016-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 동위원소 풍부 아자인돌 |
US10370371B2 (en) | 2013-08-30 | 2019-08-06 | Ptc Therapeutics, Inc. | Substituted pyrimidine Bmi-1 inhibitors |
US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
SI3068782T1 (sl) * | 2013-11-13 | 2018-10-30 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev v replikacije virusov gripe |
JP6615755B2 (ja) * | 2013-11-13 | 2019-12-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インフルエンザウイルスの複製の阻害剤 |
EP3071553A4 (en) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
KR101662597B1 (ko) * | 2014-04-02 | 2016-10-05 | 한국과학기술원 | 아자인돌 유도체 화합물, 이를 포함하는 c-KIT 저해제 조성물 및 c-KIT와 관련된 질환의 치료용 약학 조성물 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
MX2017000779A (es) | 2014-07-17 | 2017-07-27 | Chdi Foundation Inc | Metodos y composiciones para el tratamiento de trastornos relacionados con el vih. |
AU2015298876B2 (en) | 2014-08-08 | 2020-02-13 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
MA40772A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus de la grippe a |
MA40773A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus influenza a |
CA2975060C (en) | 2015-01-30 | 2019-09-03 | Pfizer Inc. | Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof |
JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤 |
EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
MX2018003590A (es) * | 2015-09-25 | 2018-11-29 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos y metodos para la inhibicion de jak. |
MX2018005461A (es) * | 2015-11-04 | 2018-08-01 | Merck Patent Gmbh | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. |
NZ741294A (en) * | 2015-11-17 | 2023-07-28 | Merck Patent Gmbh | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity |
CA3005921A1 (en) * | 2015-12-09 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication |
WO2017198122A1 (zh) * | 2016-05-19 | 2017-11-23 | 四川大学 | 抗流感小分子化合物及其制备方法和用途 |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
US10577365B2 (en) | 2016-12-23 | 2020-03-03 | Felicitex Therapeutics, Inc. | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases |
JPWO2018159805A1 (ja) | 2017-03-03 | 2020-01-09 | 国立大学法人京都大学 | 膵前駆細胞の製造方法 |
AU2018257778B2 (en) | 2017-04-24 | 2022-02-17 | Cocrystal Pharma, Inc. | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
PL3746429T3 (pl) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu) |
AR117398A1 (es) * | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
CA3106556A1 (en) | 2018-07-27 | 2020-01-30 | Cocrystal Pharma, Inc. | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication |
CN109232562A (zh) * | 2018-10-24 | 2019-01-18 | 康化(上海)新药研发有限公司 | 一种7-氮杂吲哚-5-氯-6-羧酸的合成方法 |
WO2020112716A1 (en) | 2018-11-26 | 2020-06-04 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
MX2021007925A (es) | 2018-12-31 | 2021-10-26 | Biomea Fusion Llc | Inhibidores irreversibles de la interaccion menina-mll. |
EP3906029A4 (en) | 2018-12-31 | 2022-09-21 | Biomea Fusion, LLC | INHIBITORS OF MENIN-MLL INTERACTION |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20230151034A1 (en) | 2020-03-17 | 2023-05-18 | Cocrystal Pharma, Inc. | Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
JP2024501833A (ja) * | 2020-12-24 | 2024-01-16 | ジーティー アペイロン セラピューティクス リミテッド | 芳香族複素環式化合物、並びにその薬学的組成物及び用途 |
WO2022243648A1 (fr) * | 2021-05-21 | 2022-11-24 | Centre National De La Recherche Scientifique (Cnrs) | Nouveaux derives azaindole en tant qu'agents antiviraux |
WO2023064349A1 (en) * | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL83821A0 (en) | 1986-09-10 | 1988-02-29 | Sandoz Ag | Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them |
FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
EP0763035A4 (en) | 1994-06-09 | 1997-10-01 | Smithkline Beecham Corp | ENDOTHELIN RECEPTOR ANTAGONISTS |
GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
US6180096B1 (en) * | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
WO2000040581A1 (en) | 1999-01-07 | 2000-07-13 | American Home Products Corporation | 3,4-dihydro-2h-benzo[1,4]oxazine derivatives |
US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
JP2003503456A (ja) | 1999-07-02 | 2003-01-28 | スチュアート エイ. リプトン | 神経傷害またはアポトーシスを軽減する方法 |
EP1246823A1 (en) * | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
US7041277B2 (en) | 2000-03-10 | 2006-05-09 | Cadbury Adams Usa Llc | Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same |
AU2001288714A1 (en) * | 2000-09-06 | 2002-03-22 | Ortho-Mcneil Pharmaceutical, Inc. | A method for treating allergies |
IL156517A0 (en) | 2000-12-22 | 2004-01-04 | Wyeth Corp | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
ES2360205T3 (es) | 2001-03-02 | 2011-06-01 | Agennix Ag | Sistema de ensayo de tres híbridos. |
WO2002072587A1 (en) | 2001-03-14 | 2002-09-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline |
AU2002258971A1 (en) | 2001-04-24 | 2002-11-05 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan |
US6656950B2 (en) | 2001-04-25 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine |
US6617327B2 (en) | 2001-04-26 | 2003-09-09 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline |
US6552049B2 (en) | 2001-04-26 | 2003-04-22 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans |
JP2004527561A (ja) | 2001-04-26 | 2004-09-09 | ワイス | 抗うつ作用を有する7,8−ジヒドロ−3H−6,9−ジオキサ−1,3−ジアザシクロペンタ[a]ナフタレンのアザへテロシクリルメチル誘導体 |
MXPA03009829A (es) | 2001-04-30 | 2005-03-07 | Wyeth Corp | Azaheterociclilmetil derivados de 7,8-dihidro-1,6,9-trioxa-3-azaciclopenta[a]naftaleno como agentes antidepresivos. |
EP1387845A2 (en) | 2001-05-17 | 2004-02-11 | Wyeth | PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-(2,3-f) QUINOLINE |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
AU2003241925A1 (en) * | 2002-05-31 | 2003-12-19 | Eisai R&D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
US7432375B2 (en) * | 2003-03-06 | 2008-10-07 | Eisai R & D Management Co., Ltd. | JNK inhibitors |
JP2006520796A (ja) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
PL2332940T3 (pl) | 2004-03-30 | 2013-03-29 | Vertex Pharma | Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych |
KR20070002081A (ko) | 2004-04-02 | 2007-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Rock 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌 |
ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
US20060058339A1 (en) | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity and uses therefor |
US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
JP2008508303A (ja) * | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | ピロロ−ピリジンキナーゼモジュレーター |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
WO2006124863A2 (en) | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
MX2007014619A (es) | 2005-05-20 | 2009-02-13 | Vertex Pharma | Pirrolopiridinas de utilidad como inhibidores de proteina quinasa. |
CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
AU2006297351A1 (en) | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
BRPI0706537A2 (pt) * | 2006-01-17 | 2011-03-29 | Vertex Pharma | azaindóis úteis como inibidores de janus cinases |
MX2008012860A (es) | 2006-04-05 | 2009-01-07 | Vertex Pharma | Desazapurinas de utilidad como inhibidores de janus cinasas. |
CA2839937C (en) * | 2011-07-05 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
-
2005
- 2005-03-30 PL PL10182365T patent/PL2332940T3/pl unknown
- 2005-03-30 EP EP10182255.9A patent/EP2311837B1/en active Active
- 2005-03-30 PT PT05756052T patent/PT1730146E/pt unknown
- 2005-03-30 MX MXPA06011327A patent/MXPA06011327A/es active IP Right Grant
- 2005-03-30 CN CN200910206575A patent/CN101676285A/zh active Pending
- 2005-03-30 CA CA2560454A patent/CA2560454C/en active Active
- 2005-03-30 SI SI200531340T patent/SI1730146T1/sl unknown
- 2005-03-30 DK DK10182365.6T patent/DK2332940T3/da active
- 2005-03-30 ES ES10182365T patent/ES2398712T3/es active Active
- 2005-03-30 PL PL05756052T patent/PL1730146T3/pl unknown
- 2005-03-30 EP EP10182365A patent/EP2332940B1/en active Active
- 2005-03-30 AU AU2005228904A patent/AU2005228904C1/en not_active Ceased
- 2005-03-30 AT AT05756052T patent/ATE508129T1/de active
- 2005-03-30 TW TW094110160A patent/TWI372624B/zh active
- 2005-03-30 PT PT101823656T patent/PT2332940E/pt unknown
- 2005-03-30 TW TW98110435A patent/TWI471133B/zh not_active IP Right Cessation
- 2005-03-30 KR KR1020127026302A patent/KR101298967B1/ko not_active IP Right Cessation
- 2005-03-30 ES ES05756052T patent/ES2364340T3/es active Active
- 2005-03-30 JP JP2007506535A patent/JP4937112B2/ja not_active Expired - Fee Related
- 2005-03-30 CN CN2009102065762A patent/CN101676286B/zh not_active Expired - Fee Related
- 2005-03-30 RS RS20110341A patent/RS51830B/en unknown
- 2005-03-30 TW TW101119607A patent/TWI465437B/zh not_active IP Right Cessation
- 2005-03-30 NZ NZ549880A patent/NZ549880A/en not_active IP Right Cessation
- 2005-03-30 DE DE602005027825T patent/DE602005027825D1/de active Active
- 2005-03-30 CN CN201310486314.2A patent/CN103554104A/zh active Pending
- 2005-03-30 DK DK05756052.6T patent/DK1730146T3/da active
- 2005-03-30 AR ARP050101254A patent/AR048454A1/es unknown
- 2005-03-30 RU RU2006138040/04A patent/RU2403252C2/ru active
- 2005-03-30 KR KR1020107007185A patent/KR101216372B1/ko not_active IP Right Cessation
- 2005-03-30 KR KR1020067022762A patent/KR101298951B1/ko active IP Right Grant
- 2005-03-30 NZ NZ584499A patent/NZ584499A/en not_active IP Right Cessation
- 2005-03-30 BR BRPI0509369-4A patent/BRPI0509369B1/pt not_active IP Right Cessation
- 2005-03-30 WO PCT/US2005/010846 patent/WO2005095400A1/en active Application Filing
- 2005-03-30 US US11/093,821 patent/US7507826B2/en active Active
- 2005-03-30 EP EP14164352.8A patent/EP2786995A1/en not_active Withdrawn
- 2005-03-30 EP EP05756052A patent/EP1730146B1/en active Active
-
2006
- 2006-08-31 IL IL177807A patent/IL177807A/en active IP Right Grant
- 2006-10-24 NO NO20064852A patent/NO340403B1/no not_active IP Right Cessation
-
2007
- 2007-05-04 HK HK07104783.6A patent/HK1098471A1/xx not_active IP Right Cessation
-
2008
- 2008-03-10 JP JP2008060340A patent/JP5042888B2/ja not_active Expired - Fee Related
- 2008-11-19 US US12/273,799 patent/US8188281B2/en active Active
-
2010
- 2010-05-14 RU RU2010119561/04A patent/RU2010119561A/ru not_active Application Discontinuation
- 2010-10-11 HK HK10108367.6A patent/HK1142882A1/xx not_active IP Right Cessation
- 2010-12-27 AR ARP100104957A patent/AR079749A2/es unknown
-
2011
- 2011-07-20 CY CY20111100709T patent/CY1111716T1/el unknown
- 2011-07-29 HR HRP20110566TT patent/HRP20110566T8/hr unknown
- 2011-12-01 JP JP2011264040A patent/JP5566992B2/ja not_active Expired - Fee Related
- 2011-12-01 IL IL216734A patent/IL216734A0/en unknown
-
2012
- 2012-04-06 US US13/441,287 patent/US8501446B2/en not_active Expired - Fee Related
- 2012-06-08 AU AU2012203384A patent/AU2012203384A1/en not_active Abandoned
- 2012-06-08 AU AU2012203382A patent/AU2012203382B2/en not_active Ceased
-
2013
- 2013-01-30 CY CY20131100082T patent/CY1113560T1/el unknown
- 2013-06-03 US US13/908,267 patent/US8722889B2/en not_active Expired - Fee Related
- 2013-09-05 JP JP2013183669A patent/JP2013249315A/ja not_active Withdrawn
-
2014
- 2014-02-18 US US14/182,517 patent/US8987454B2/en not_active Expired - Fee Related
-
2015
- 2015-02-05 US US14/614,740 patent/US20150152103A1/en not_active Abandoned
- 2015-03-16 JP JP2015051664A patent/JP2015113347A/ja not_active Withdrawn
-
2016
- 2016-05-24 NO NO20160876A patent/NO20160876A1/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI372624B (en) | Azaindoles useful as inhibitors of jak and other protein kinases | |
ZA200704888B (en) | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | |
SI2332940T1 (sl) | Azaindoli, uporabni kot inhibitorji jak in drugih protein-kinaz | |
HK1099764A1 (en) | Quinoxalines useful as inhibitors of protein kinases | |
PT1562589E (pt) | Diaminotriazoles úteis como inibidores de proteína-quinases | |
SI1811998T1 (sl) | Triazoli uporabni kot inhibitorji proteinskih kinaz | |
PT1664043E (pt) | Composições úteis como inibidores de proteínas quinases | |
PL374023A1 (en) | Inhibitors of jak and cdk2 protein kinases | |
HK1129298A1 (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
IL194699A0 (en) | Tetrahydropteridines useful as inhibitors of protein kinases | |
EP1931205A4 (en) | TRANSGLUTAMINASE INHIBITORS AND METHOD OF USE THEREOF | |
EP1940787A4 (en) | NOVEL IDO INHIBITORS AND METHODS OF USE | |
IL192351A0 (en) | Azaindole inhibitors of aurora kinases | |
EP1720855A4 (en) | HEMMER OF ACT ACTIVITY | |
EP1737861A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP1827436A4 (en) | ACTIVITY INHIBITORS AKT | |
HK1110578A1 (en) | Benzotriazine inhibitors of kinases | |
EP1794589A4 (en) | PROTEIN ARRAYS AND METHOD OF USE THEREOF | |
EP1812012A4 (en) | PROTEIN TYROSINE PHOSPHATASE INHIBITOR AND METHOD FOR THEIR USE | |
EP1793841A4 (en) | PEPTIDHEMMER OF C-JUN DIMERIZATION AND ITS USES | |
AP2006003756A0 (en) | Anti-parasitic compounds and methods of their use | |
EP1877424A4 (en) | INHIBITORS OF PROTEIN KINASES AND USES THEREOF | |
ZA200806871B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
EP1789437A4 (en) | INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF | |
EP1824849A4 (en) | INHIBITORS OF AKT ACTIVITY |